Synthetic Biologics, Inc. (NYSEAMERICAN:SYN)’s share price fell 9.9% on Monday . The company traded as low as $0.33 and last traded at $0.33. 797,920 shares changed hands during trading, an increase of 61% from the average session volume of 496,886 shares. The stock had previously closed at $0.36.
Separately, Maxim Group downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Friday, October 2nd.
Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter.
Synthetic Biologics Company Profile (NYSEAMERICAN:SYN)
Synthetic Biologics, Inc, a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.
Further Reading: What is the float in trading stocks?
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.